AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20619378 — intervention group
Group type: EXPERIMENTAL
Intervention: Invaplex 50 (38.5%)
Number of subjects: 32
Study 20619378 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (30.8%)
Number of subjects: 32
Study 20619396 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 73
Study 20619396 — intervention group
Group type: COMPARATOR
Intervention: Control groups (without PTSD and unexposed)
Number of subjects: 73
Study 20620231 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization (CR)
Number of subjects: 759
Study 20620231 — intervention group
Group type: COMPARATOR
Intervention: No prior coronary revascularization (CR)
Number of subjects: 759
Study 20620717 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1492
Study 20624109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (three doses of 4 g)
Number of subjects: 1
Study 20624109 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrate (two units)
Number of subjects: 1
Study 20624517 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative delirium diagnosis based on DSM-IV criteria
Number of subjects: 563
Study 20624517 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age, preoperative cognitive impairment, ongoing episode of major depression, anaemia, atrial fibrillation, prolonged intubation, postoperative hypoxia
Number of subjects: 563
Study 20625116 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH1 mutations (IDH1m) in patients with normal cytogenetics (CN-AML)
Number of subjects: 520
Study 20625116 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH2 mutations (IDH2m) in patients with normal cytogenetics (CN-AML)
Number of subjects: 520
Study 20625116 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable genotype in CN-AML (NPM1m or CEBPAm without FLT3-ITD or IDH1m)
Number of subjects: 520
Study 20625116 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis including age, WBC count, four-gene favorable genotype, and IDH2m
Number of subjects: 520
Study 20625390 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher year 7 fibrinogen
Number of subjects: 0
Study 20625390 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher year 7 CRP
Number of subjects: 0
Study 20625390 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher year 5 fibrinogen
Number of subjects: 0
Study 20625390 — intervention group
Group type: EXPERIMENTAL
Intervention: Year 7 CRP among participants with greater than 10 pack-years of cigarette exposure
Number of subjects: 0
Study 20626754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine (120 mg/m² on days 1-2 of a 21-day cycle, for up to six cycles)
Number of subjects: 69
Study 20627488 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants (BM group)
Number of subjects: 76
Study 20627488 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified formula (F group)
Number of subjects: 76
Study 20627920 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (180 microg)
Number of subjects: 15
Study 20627920 — intervention group
Group type: EXPERIMENTAL
Intervention: During exacerbation
Number of subjects: 15
Study 20627920 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery results
Number of subjects: 15
Study 20627920 — intervention group
Group type: COMPARATOR
Intervention: Baseline (clinically stable)
Number of subjects: 15
Study 20629472 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 1350
Study 20629472 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 1350
Study 20629472 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5%
Number of subjects: 1350
Study 20630061 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus administered intravenously at 25 mg weekly (Study A)
Number of subjects: 21
Study 20630061 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus administered orally at 30 mg weekly and erlotinib at 150 mg daily (Study B)
Number of subjects: 21
Study 20630062 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) intervention in the intervention region
Number of subjects: 4174
Study 20630062 — intervention group
Group type: COMPARATOR
Intervention: Control region
Number of subjects: 4174
Study 20630688 — intervention group
Group type: EXPERIMENTAL
Intervention: DCVT
Number of subjects: 725
Study 20630688 — intervention group
Group type: EXPERIMENTAL
Intervention: MCVT
Number of subjects: 725
Study 20631018 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT)
Number of subjects: 493
Study 20631018 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I generation test
Number of subjects: 493
Study 20631018 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IGF-I/GH determinations
Number of subjects: 493
Study 20631203 — intervention group
Group type: EXPERIMENTAL
Intervention: PROP supertasters (n = 27)
Number of subjects: 75
Study 20631203 — intervention group
Group type: COMPARATOR
Intervention: Nontasters (n = 20)
Number of subjects: 75
Study 20631203 — intervention group
Group type: EXPERIMENTAL
Intervention: Gustin gene polymorphism (rs2274333)
Number of subjects: 75
Study 20631232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film osmolarity testing
Number of subjects: 314
Study 20631232 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival staining
Number of subjects: 314
Study 20631232 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal staining
Number of subjects: 314
Study 20631232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI)
Number of subjects: 314
Study 20631232 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian dysfunction assessment
Number of subjects: 314
Study 20631232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear film breakup time (TBUT)
Number of subjects: 314
Study 20631232 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer test without anesthesia
Number of subjects: 314
Study 20631232 — intervention group
Group type: COMPARATOR
Intervention: Standard threshold-based classification
Number of subjects: 314
Study 20631232 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment of dry eye severity
Number of subjects: 314
Study 20631556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine therapy
Number of subjects: 17
Study 20631574 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Number of subjects: 0
Study 20631574 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard opioid detoxification)
Number of subjects: 0
Study 20632098 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterologist-guided sedation
Number of subjects: 91
Study 20632098 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist-guided sedation
Number of subjects: 91
Study 20633428 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT (6 bilateral treatments, outpatient, twice-weekly)
Number of subjects: 20
Study 20633821 — intervention group
Group type: EXPERIMENTAL
Intervention: BMIPP SPECT
Number of subjects: 507
Study 20633821 — intervention group
Group type: COMPARATOR
Intervention: BMIPP + initial diagnosis
Number of subjects: 507
Study 20634241 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 135
Study 20634241 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 135
Study 20634373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2) on days 1, 29, 57 and 85; Fludarabine orally, 40 mg/m(2) on days 1-5, 29-34, 57-61 and 85-89
Number of subjects: 29
Study 20634373 — intervention group
Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 29
Study 20634373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and rituximab combination therapy
Number of subjects: 29
Study 20634483 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators
Number of subjects: 15381
Study 20634483 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with pacemaker
Number of subjects: 15381
Study 20634483 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with defibrillator
Number of subjects: 15381
Study 20634483 — intervention group
Group type: COMPARATOR
Intervention: No device
Number of subjects: 15381
Study 20634684 — intervention group
Group type: EXPERIMENTAL
Intervention: KNOW FIVE - STAY ALIVE program
Number of subjects: 0
Study 20634684 — intervention group
Group type: COMPARATOR
Intervention: FAST program
Number of subjects: 0
Study 20634684 — intervention group
Group type: COMPARATOR
Intervention: NIH brochure 'Know Stroke. Know the signs, Act in time'
Number of subjects: 0
Study 20634719 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA less than 10%
Number of subjects: 1042
Study 20634719 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA between 10 and 20%
Number of subjects: 1042
Study 20634719 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA between 20 and 30%
Number of subjects: 1042
Study 20634719 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA more than 30%
Number of subjects: 1042
Study 20634719 — intervention group
Group type: EXPERIMENTAL
Intervention: PWV in presence of hypertension
Number of subjects: 1042
Study 20634719 — intervention group
Group type: EXPERIMENTAL
Intervention: PWV in presence of diabetes
Number of subjects: 1042
Study 20634719 — intervention group
Group type: EXPERIMENTAL
Intervention: PWV in participants with heart disease
Number of subjects: 1042
Study 20634785 — intervention group
Group type: EXPERIMENTAL
Intervention: Diannexin treatment
Number of subjects: 0
Study 20636419 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate or no antimicrobial treatment at origin
Number of subjects: 337
Study 20636419 — intervention group
Group type: COMPARATOR
Intervention: Adequate antimicrobial regimen according to guidelines
Number of subjects: 337
Study 20636419 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferred patients
Number of subjects: 337
Study 20636419 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications and operations
Number of subjects: 337
Study 20637534 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical device treatment
Number of subjects: 46
Study 20637584 — intervention group
Group type: EXPERIMENTAL
Intervention: High omega-3 to omega-6 PUFA ratio (Q75)
Number of subjects: 38
Study 20637584 — intervention group
Group type: EXPERIMENTAL
Intervention: Low omega-3 to omega-6 PUFA ratio (Q25)
Number of subjects: 38
Study 20637584 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific bronchial challenge with grass pollen
Number of subjects: 38
Study 20637584 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 20638196 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of CHOP chemotherapy and radiation to a dose of 45 Gy in 25 fractions using a shrinking field technique
Number of subjects: 33
Study 20644013 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody valve implantation
Number of subjects: 136
Study 20644097 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 20645885 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib on top of optimal atorvastatin therapy
Number of subjects: 1624
Study 20645885 — intervention group
Group type: COMPARATOR
Intervention: Placebo on top of optimal atorvastatin therapy
Number of subjects: 1624
Study 20646242 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic thoracentesis (TT)
Number of subjects: 26
Study 20646244 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracocentesis
Number of subjects: 10
Study 20647554 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C
Number of subjects: 117
Study 20647554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 20647561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical SYNTAX Score (CSS) calculated by multiplying the SYNTAX Score to a modified ACEF score.
Number of subjects: 512
Study 20647561 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical SYNTAX Score (CSS)
Number of subjects: 512
Study 20648206 — intervention group
Group type: EXPERIMENTAL
Intervention: mild lumbar decompression procedure
Number of subjects: 75
Study 20650435 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 variant carriers (n = 80)
Number of subjects: 126
Study 20650435 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 variant
Number of subjects: 126
Study 20650436 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Express paclitaxel-eluting stent
Number of subjects: 474
Study 20650686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression
Number of subjects: 2212
Study 20650686 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy
Number of subjects: 2212
Study 20650871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal feeding to induce polyclonal gluten-specific T cells
Number of subjects: 0
Study 20650871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal feeding (wheat, barley, rye)
Number of subjects: 0
Study 20650871 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunodominant peptides from omega-gliadin (wheat) and C-hordein (barley)
Number of subjects: 0
Study 20651074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/d with a 3-month low-dose prednisone taper
Number of subjects: 48
Study 20651074 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study 20651099 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored nutrition education program
Number of subjects: 79
Study 20651099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 79
Study 20651274 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy monitoring
Number of subjects: 60
Study 20651274 — intervention group
Group type: COMPARATOR
Intervention: Transcranial Doppler monitoring
Number of subjects: 60
Study 20653948 — intervention group
Group type: EXPERIMENTAL
Intervention: IMP321 (LAG-3Ig) administered subcutaneously every two weeks for 24 weeks (12 injections) alongside paclitaxel (80 mg/m2 weekly for 3 weeks out of 4)
Number of subjects: 30
Study 20653948 — intervention group
Group type: EXPERIMENTAL
Intervention: IMP321 (LAG-3Ig)
Number of subjects: 30
Study 20653948 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (not specified in detail)
Number of subjects: 30
Study 20656559 — intervention group
Group type: EXPERIMENTAL
Intervention: MODS culture
Number of subjects: 218
Study 20656559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowenstein-Jensen culture
Number of subjects: 218
Study 20656559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric-aspirate specimens
Number of subjects: 218
Study 20656559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric-aspirate specimens (second specimen)
Number of subjects: 218
Study 20656559 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric-aspirate PCR
Number of subjects: 218
Study 20656559 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate gastric-aspirate specimens for MODS culture
Number of subjects: 218
Study 20656559 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 218
Study 20657770 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Interruption (TI)
Number of subjects: 25
Study 20658481 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT scans
Number of subjects: 15
Study 20658481 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological analysis
Number of subjects: 15
Study 20658621 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 30
Study 20658621 — intervention group
Group type: EXPERIMENTAL
Intervention: T2*-MRI
Number of subjects: 30
Study 20658621 — intervention group
Group type: EXPERIMENTAL
Intervention: MUGA scan
Number of subjects: 30
Study 20658621 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin measurement
Number of subjects: 30
Study 20658621 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic iron content measurement
Number of subjects: 30
Study 20659883 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum glucose level >140 mg/dl
Number of subjects: 672
Study 20660050 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymidine analogs (iododeoxyuridine or bromodeoxyuridine) administered 8 days to 4 years prior to death.
Number of subjects: 10
Study 20660050 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of β-cell longevity using (14)C levels from DNA purified from pancreatic islets.
Number of subjects: 10
Study 20660053 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Aldosteronism (PA)
Number of subjects: 52
Study 20660053 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral adrenalectomy for aldosterone-producing adenoma (APA)
Number of subjects: 52
Study 20660788 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients developing IRIS episodes
Number of subjects: 0
Study 20660788 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1(+) CD4(+) T cells in IRIS patients
Number of subjects: 0
Study 20660788 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory T cells of IRIS patients
Number of subjects: 0
Study 20660788 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS patients
Number of subjects: 0
Study 20660808 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid PET/CT imaging
Number of subjects: 107
Study 20660808 — intervention group
Group type: COMPARATOR
Intervention: CT angiography alone
Number of subjects: 107
Study 20660808 — intervention group
Group type: COMPARATOR
Intervention: Perfusion imaging alone
Number of subjects: 107
Study 20660808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PET and CT protocols
Number of subjects: 107
Study 20661232 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCH-F regimen (infusional etoposide, VCR, adriamycin, prednisone, CY, fludarabine)
Number of subjects: 22
Study 20661680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring
Number of subjects: 26
Study 20661680 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed EEG monitoring
Number of subjects: 26
Study 20661680 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 26
Study 20661680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fore-Sight monitor for cerebral oximetry
Number of subjects: 26
Study 20661680 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate flux
Number of subjects: 26
Study 20662793 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with carboplatin (i.v. gemcitabine at 1000 mg/m² on days 1 and 8, and i.v. carboplatin at AUC 5 on day 1 of a 21-day cycle)
Number of subjects: 48
Study 20662793 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine combined with carboplatin
Number of subjects: 48
Study 20662848 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the internal limiting membrane (ILM) during epiretinal membrane surgery
Number of subjects: 22
Study 20663751 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive website for weight loss maintenance (consistent users n = 212)
Number of subjects: 348
Study 20663751 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive website for weight loss maintenance (minimal users n = 75)
Number of subjects: 348
Study 20663751 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of log-ins
Number of subjects: 348
Study 20663751 — intervention group
Group type: EXPERIMENTAL
Intervention: Minutes on the website
Number of subjects: 348
Study 20663751 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of weight entries
Number of subjects: 348
Study 20663751 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of exercise entries
Number of subjects: 348
Study 20663751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sessions with additional use of website features after weight entry
Number of subjects: 348
Study 20663944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral busulfan 12 mg/kg plus melphalan 140 mg/m2
Number of subjects: 767
Study 20663944 — intervention group
Group type: COMPARATOR
Intervention: Melphalan 200 mg/m2
Number of subjects: 767
Study 20664026 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2285
Study 20664026 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 2285
Study 20664181 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy for MCI patients combining psychoeducation, cognitive rehabilitation, and cognitive-behavioral therapy.
Number of subjects: 93
Study 20664181 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (30 patients).
Number of subjects: 93
Study 20666569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ASA (75-325 mg daily)
Number of subjects: 340
Study 20666569 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper GI symptoms
Number of subjects: 340
Study 20667078 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (specifics not provided)
Number of subjects: 2400
Study 20667078 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2400
Study 20668228 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T cells genetically engineered to express anti-CD19 CAR
Number of subjects: 1
Study 20668228 — intervention group
Group type: COMPARATOR
Intervention: Preparative chemotherapy regimen
Number of subjects: 1
Study 20668251 — intervention group
Group type: EXPERIMENTAL
Intervention: Food selection meeting SMI standards
Number of subjects: 2049
Study 20668251 — intervention group
Group type: EXPERIMENTAL
Intervention: Food selection meeting IOM recommendations
Number of subjects: 2049
Study 20668251 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat selection
Number of subjects: 2049
Study 20668251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean energy selection
Number of subjects: 2049
Study 20668251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean plate waste
Number of subjects: 2049
Study 20668251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean energy intake
Number of subjects: 2049